Nanoscope Therapeutics Achieves Breakthrough in Vision Restoration
Researchers at Nanoscope Therapeutics Inc. have published a groundbreaking study in Molecular Therapy demonstrating a mutation-independent optogenetic monotherapy that restores vision in patients with severe retinal degeneration. The study, led by Dr. Santosh Mahapatra, highlights the therapeutic benefits for retinitis pigmentosa patients with progressive photoreceptor loss—offering hope where no treatment options previously existed. Nanoscope’s Multi-Characteristic Opsin (MCO) technology overcomes key limitations of traditional optogenetics by enabling broadband, high-resolution vision restoration. This innovation marks a major step forward in treating inherited retinal degenerative diseases (IRDs), a leading cause of blindness worldwide.
Nanoscope Therapeutics Achieves Breakthrough in Vision Restoration